Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's ...

Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "OFEV Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The report provides insights into OFEV for ...

(MENAFN- GlobeNewsWire - Nasdaq) OFEV's market opportunities lie in its broadening approval for various fibrosing lung diseases, including expansion to pediatric patients, strengthening its position ...

Nintedanib capsules are used to treat Idiopathic Pulmonary Fibrosis. Commenting on the approval Marc Falkin, CEO, Cipla North America, said, "This approval strengthens our respiratory franchise and ...

The standard dosage of Ofev (nintedanib) is a 150-milligram (mg) capsule taken twice daily, though your doctor may adjust this based on individual health factors and side effects. Ofev is intended for ...

The cost of Ofev can vary based on several factors, including your insurance coverage. The drug’s cost with and without insurance can depend on several factors, such as whether Ofev has a savings ...

Ofev (nintedanib) is a prescription drug that’s used to treat certain lung conditions. Ofev’s cost may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The second round of Medicare Part D price negotiations ...

Boehringer Ingelheim has won a positive European Medicines Agency (EMA) recommendation for blockbuster Ofev’s (nintedanib) use in children and adolescents with progressive fibrosing interstitial lung ...

RIDGEFIELD, Conn. and INGELHEIM, Germany, July 25, 2023 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug ...

The supplemental New Drug Application is based on results from the InPedILD phase III trial, which assessed dose-exposure and safety in pediatric patients aged 6-17 If approved, OFEV would be the ...